Kutatási jelek – Signal Engine

• Lung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review — NSCLC
• Photodynamic therapy in breast cancer treatment — Breast cancer
• Immunotherapy in Ovarian Cancer — Ovarian cancer
• Decoding the Raf-Mek-Erk-Rsk pathway in prostate cancer: from molecular mechanisms to clinical opportunities — Prostate cancer
• Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer — Colorectal cancer
• Improving drug options for colorectal cancer patients — Salk Institute — Colorectal cancer
• Pembrolizumab and Stage II Melanoma: KEYNOTE-716 Trial Results Will Open Path to a New Treatment Paradigm for High‑Risk Tumors — Melanoma
• The new insight of treatment in Cholangiocarcinoma — Cholangiocarcinoma
• Acute Myeloid Leukemia (AML) — Acute myeloid leukemia
• Merck Announces KEYTRUDA (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib — Hepatocellular carcinoma
• Lung Cancer | University of Iowa Clinical Research and Trials — NSCLC
• Multiple Myeloma | University of Iowa Clinical Research and Trials — Multiple myeloma
• Phase II Study of Neoadjuvant Carboplatin for Localized High Risk Prostate Cancer with Germline BRCA1/2 Mutations — Prostate cancer
• Leiomyosarcoma Research, Support & Advocacy | LMSDR — Leiomyosarcoma
• Lung | Cancer Clinical Trials & Research Studies | NYU Langone Health | Page 1 — NSCLC
• ‘STARPORT’ trial probes new approach for aggressive prostate cancer — Prostate cancer
• High-risk neuroblastoma: targeted therapy could be used in first line treatment - Institut Curie — Neuroblastoma
• ROSALINE Trial for Patients with Early-Stage Lobular Breast Cancer — Breast cancer
• Chronic myeloid leukemia: Symptoms, prognosis, and more — Chronic myeloid leukemia
• Kidney Cancer Today — Renal cell carcinoma